Akebia Strikes $350m+ Asian Vadadustat Alliance
This article was originally published in PharmAsia News
Executive Summary
Mitsubishi Tanabe's agreement to acquire selected Asian rights to Akebia's vadadustat will boost the Japanese firm's existing presence in kidney disease while providing important funding for the US company's planned Phase III program with the novel anemia drug.
You may also be interested in...
Vadadustat Emerges As Japan HIF-PHI Contender With First Filing Globally
Competition intensifies in novel anemia therapy space in Japan with first filing globally for Akebia/Mitsubishi Tanabe’s contender vadadustat, which could see its first launch worldwide in the country.
Deal Watch: Seattle Genetics' Controversial Collaboration With Immunomedics Topples
A licensing deal between the two cancer-focused biotechs falls apart amidst investor unrest at Immunomedics. Novartis opts to license Conatus' Phase II NASH candidate and picks up a CAR-T candidate from Celyad, while Shire adds to its dry eye franchise in deal with Parion.
Akebia Holds Development Reins In Anemia While Otsuka Jumps On Vadadustat Sleigh
Co-development deal worth $265m in near-term cash will allow Akebia to tap into Otsuka's established kidney disease infrastructure, while holding the reins on key aspects of commercialization.